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We hypothesized that C-reactive protein (CRP) may affect the cell cycle and induce apoptotic
changes of monocytes. CRP (25 lg/ml) signiﬁcantly increased expressions of B-cell translocation
gene 2 (BTG2) mRNA and protein in human monocytes through pathways involving CD32/NADPH
oxidase 2/p53, which eventually induced G2/M phase arrest and apoptotic cell death. Such pro-apop-
totic effect of CRP was not found in thioglycollate-elicited intraperitoneal monocytes/macrophages
harvested from BTG2-knockout male C57BL/6 mice (n = 5). Within atheromatous plaques obtained
from CRP-transgenic male LDLR/ C57BL/6 mice (n = 5) and human coronary arteries, BTG2 co-local-
ized with CRP, p53 andmonocytes/macrophages. Therefore the pro-apoptotic pathway of CRP-CD32-
Nox2-p53-BTG2 may contribute to the retardation of the atherogenic process.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Monocytes egress from bone marrow, circulate in the blood,
and have a short life-span (17–72 h) [1]. The milieu of cytokines
and growth factors present in inﬂammatory lesions, such as
interleukin-1 beta (IL-1b), IL-8, IL-10, tumor necrosis factor alpha
(TNF-a), interferon gamma (IFN-c), macrophage and granulocyte/
macrophage-colony stimulating factors (GM-CSF), enable recruited
monocytes to escape from spontaneous apoptosis and undergo
differentiation and proliferation [1]. Conversely, any factors that
facilitate apoptotic changes in monocytes may reduce the
inﬂammatory response and eventually retard the process of
inﬂammation in the arterial wall, e.g. atherosclerosis.
C-reactive protein (CRP), a prototype acute phase reactant [2],
directly induces a number of innate immune responses including
the production of potentially pro-apoptotic cytokines and
inﬂammatory mediators [3] through the activation of Fc-gammareceptors (FccRs) [4,5]. CRP is detected in atherosclerotic plaques
[6] and stimulates monocytes/macrophages and vascular smooth
muscle cells (VSMCs) to produce pro-apoptotic cytokines such as
IL-1b and TNF-a, and reactive oxygen species (ROS) [7,8]. We
previously reported CRP-induced apoptotic changes in VSMCs via
activation of NADPH oxidase (Nox) and subsequent ROS generation
[5]. However, it is not clear whether CRP is pro-apoptotic for
monocytes.
We therefore investigated if cell kinetics and life span of mono-
cytes can be changed by CRP. The present study demonstrates
in vitro and ex vivo evidences that CRP upregulates B-cell transloca-
tion gene 2 (BTG2), a member of the antiproliferative (APRO) gene
family, through elaborate signaling pathways involving a CD32-
Nox2-ROS-p53 cascade. As a consequence, monocytes exposed to
CRP developed G2/M phase arrest and eventually underwent apop-
totic death.
2. Materials and methods
2.1. Preparation of monocytes and CRP
Circulating human monocytes were freshly isolated from
healthy donors using 1077 Histopaque (Sigma–Aldrich, St. Louis,
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(Miltenyi Biotech, Auburn, CA) as described previously [9], and
maintained in serum-free complete media (Gibco BRL, Grand Is-
land, NY). Flow cytometry showed that the monocytes were >80%
pure as determined by staining with an anti-CD14 antibody. In-
formed consent was obtained from the blood donors and the pro-
tocol conformed to the principles outlined in the ‘Declaration of
Helsinki’. Human monocytes were cultured in RPMI1640 medium
containing 10% FBS as described previously [9]. In a subset of
experiment, cell cycle of monocytes was synchronized at G1/S
phase (G1 phase; 43%, S phase; 52%, G2/M phase 5%) by treating
with 100 ng/ml nocodazole for 18 h as described [10] and was then
removed to progress cell division cycle. Murine monocytes/macro-
phages were collected from 6-week-old C57BL/6 male mice [wild-
type, p53 knockout (p53-/-), and BTG2 knockout (BTG2-/-), n = 5 per
group] at 5 days after intraperitoneal injection of 3% thioglycollate
(1.0 ml/mouse, Sigma–Aldrich, St. Louis, MO). The harvested cells
seeded into 6-well plates in RPMI-1640 supplemented with 20%
FBS were allowed to adhere for 2 h before non-adherent cells were
washed out. C57BL/6 male mice containing LDLR//hCRPtg (n = 5)
were fed a high-cholesterol/low-fat diet comprising cholesterol-
enriched regular mouse chow (0.5% cholesterol and 4.4% fat;
TD97234, Harlan–Teklad, Madison, WI) for 24 weeks before being
sacriﬁced for immunohistochemical analysis. The animal study
was approved by the University of Ulsan Animal Subjects Commit-
tee and conformed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996).
Human recombinant CRP stock (Calbiochem Millipore, Billerica,
MA) was conﬁrmed as ‘‘IgG-free’’ (<1.0 ng/lg CRP), conformation-
ally intact (by electrophoresis on non-denaturing gels) [9], and
endotoxin-free (<1.0 ng/ml; determined by a timed-gel endotoxin
kit assay (Sigma–Aldrich). The complete cDNA sequence of human
BTG2 (GenBank accession no. NM_006763) was ampliﬁed by PCR
and the PCR product cloned into pCRII-TOPO (Invitrogen, Carlsbad,
CA). The nucleotide sequence of the inserted BTG2 cDNA was con-
ﬁrmed by direct sequencing followed by subcloning into the
expression vector, pcDNA3.1 (Invitrogen).
Human isolated monocytes were transfected using the Lipofect-
amine 2000 reagent according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA). Brieﬂy, 5  105 monocytes in a 6-well
plate in RPMI 1640 medium were treated with either 4 lg p53
dominant negative DNA (pCMV-p53mt135; Clontech, Mountain
View, CA) plus 10 lL Lipofectamine 2000, or 100 pmole siRNAs
against Nox2, DGKf, PKCd, and BTG2 (Santa Cruz Biotechnology,
Dallas, TX) plus 5 ll Lipofectamine 2000 for 4–6 h. The medium
was then changed to RPMI 1640 containing 10% FBS and the cells
were further incubated at 37 C in a CO2 incubator for 24 h. The
transfection efﬁciency, determined using a pcDNA3.1 vector
encoding green ﬂuorescent protein, was estimated to be >70%. In
a subset of experiments, monocytes were incubated with N-acet-
yl-L-cysteine (NAC, Sigma–Aldrich, St. Louis, MO), anti-human
CD64 or anti-CD32 antibodies (R&D System, Minneapolis, MN).
2.2. Measurement of mRNA expression levels
The expression of mRNA encoding p53, BTG2, Nox2, b-actin, and
GAPDH was determined by real-time PCR with SYBR Green I Fast-
start Master Mix (Roche Molecular Diagnostics, Pleasanton, CA)
and speciﬁc primers. PCR ampliﬁcation conditions were 45 cycles
at 95 C for 15 s, 60 C for 5 s, and 72 C for 25 s with the following
speciﬁc primers;
Human p53: 50-CAGTCTACCTCCCGCCATAA-30 (forward)
50-CCACAACAAAACACCAGTGC-30 (reverse)
Human BTG2: 50-CAGAGCACTACAAACACCAC-30 (forward)50-AGACTGCCATCACGTAGTTC-30 (reverse)
Mouse p53: 50-GTTCCGGGAGCTGAATGAGG-30 (forward)
50-CAGGCCCCACTTTCTTGACC-30 (reverse)
Mouse BTG2/TIS21: 50-TGGACCCCATCATCAGCAAG-30 (forward)
50-TGCCCAGCATCATCTGGTTC-30 (reverse)
GAPDH: 50-GACCCCTTCATTGACCTC-30 (forward)
50-GCTAAGCAGTTGGTGGTG-30 (reverse)
b-Actin or GAPDH mRNAs were employed as the internal stan-
dards and analyzed under the identical conditions using a pair of
speciﬁc primers. The Ct value (the cycle number at which emitted
ﬂuorescence exceeds an automatically determined threshold) for
the target cDNA was corrected using the Ct value for GAPDH and
expressed as DCt. Data were expressed as fold changes in the
amount of mRNA, which was calculated using the following for-
mula: -Fold change = 2(DCt for untreated cells  DCt for treated cells).
2.3. Immunohistochemistry
To detect proteins of p53, BTG2, CRP and monocytes/macro-
phages in the plaque, thoracic aorta of LDLR//CRPtg mice and hu-
man atherosclerotic plaques in coronary artery were analysed.
Cross sections of mouse thoracic aorta specimen were blocked
with 5% goat serum, incubated overnight at 4 C with a speciﬁc
antibodies detecting mouse p53 (1:250, PAb240, Abcam, Cam-
bridge, UK), mouse BTG2 (1:100, ab58219, Abcam, Cambridge,
UK), mouse F4/80 (1:50; Abcam, Cambridge, UK), or CRP (1:500;
Sigma–Aldrich). Mouse thoracic aorta specimen were incubated
with appropriate biotin-labelled secondary antibodies and coun-
terstained with hematoxylin QS (Dako, Glostrup, Denmark). The
reactions were visualized using the LSAB2 system/streptavidin-
HRP kit with DAB staining. Human atherosclerotic coronary artery
was incubated with an anti-human antibodies for CD68 (Abcam),
or BTG2 (Abcam) and cell-associated antibodies were detected by
secondary antibodies labeled with Alexa Flour 488 or Rhodamine
TRITC (Abcam). Nuclei were stained with 40,6-diamidino-2-phenyl-
indole (DAPI) and ﬂuorescent images were obtained using an
Olympus DP71 microscope and Olympus DPController software.
2.4. Immunoblotting assay
Immunoblotting was performed using mouse anti-human
monoclonal IgG antibodies (1:1000) against p53 (Cell Signaling
Technology, Boston, MA), BTG2, or DGKf (Santa Cruz Biotechnol-
ogy, Dallas, TX) and developed using goat anti-mouse IgG-HRP
(1:10,000, Jackson ImmunoResearch Laboratories, Inc, West Grove,
PA) and a chemiluminescence detection kit (ECL-kit, PIERCE from
Thermo Fisher Scientiﬁc Inc., Waltham, MA). The amount of pro-
tein was quantiﬁed using the MULTI-IMAGE analysis system and
Quantitation software (Bio-Rad Laboratories Inc., Hercules, CA).
2.5. Proliferation and apoptosis of monocytes
Human monocytes or mouse peritoneal macrophages were
labelledwith 30 lMBrdU for 1 h at 37 C, washedwith PBS contain-
ing 0.5% BSA (wash buffer), and ﬁxedwith 70% ethanol for 30 min at
room temperature. DNA was denatured in 2 N HCl for 20 min at RT
and neutralized with 0.1 M sodium borate (pH 8.5) for 2 min.
Cell-associated BrdU was labelled with 20 ll FITC-conjugated
anti-BrdU IgG (R&D System, Abingdon, UK). Nonspeciﬁc binding of
anti-BrdU IgG was blocked by preincubation with 10 lg/ml of Fc
Fragments (ChromPure Human IgG; Jackson ImmunoResearch
Laboratories, West Grove, PA) for 30 min. To detect apoptosis in
monocytes, cells were ﬁxed with 90% ethanol for 20 min at room
temperature and stained with 5 ll propidium iodide (PI, 25 lg/ml,
R&D System, Abingdon, UK) for 15 min at room temperature in
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etry on a FACScan ﬂow cytometer and data analysis was performed
with CELLQUEST software (BD Biosciences, San Jose, CA).
2.6. Statistical analysis
Values are expressed as mean ± S.D., and the differences
between two groups were evaluated by the unpaired t test and
the differences among multiple groups were by two-way ANOVA.
Statistical differences P < 0.05 by SPSS (version 10.0, SSPS Inc.,
Chicago, IL) were regarded as signiﬁcant.
3. Results
3.1. CRP upregulates p53 and BTG2 expressions in monocytes
Freshly-isolated human monocytes were incubated with
recombinant human CRP (0–25 lg/ml), and then subjected to
immunoblot and real-time RT-PCR analyses to evaluate proteinFig. 1. CRP-induced upregulations of p53 and BTG2 expressions in monocytes, and co-loc
plaque. (A) Freshly-isolated humanmonocytes were incubated with 0–25 lg/ml CRP, and
cell lysates were examined by immunoblot analysis and the fold changes were presen
quantitative and real time RT-PCR and the percent changes were expressed as a dot-line g
test (⁄P < 0.05, ⁄⁄P < 0.01 vs. control; NS, not statistically signiﬁcant). (B) Thioglycollate-
(‘wild type’) male mice, p53/ (‘p53 KO’) or BTG2/ (‘BTG2 KO’) littermates (n = 5 each)
and BTG2 in the cell lysates were detected by immunoblot analyses. Data represent the
thoracic aorta derived from hCRPtg LDLR/ mice was stained with speciﬁc antibodies a
counter-stain. Scale bar, 100 lm. (D) Human atherosclerotic plaque in coronary artery
for monocytes/macrophages and cell-bound antibodies were detected by either Alexa
40 ,6-diamidino-2-phenylindole (DAPI) as a background (blue color).and mRNA expressions of p53 and BTG2. CRP increased both total
and phosphorylated forms of p53 proteins, and BTG2 protein in a
dose-dependent manner (Fig. 1A) (P < 0.01). Moreover, mRNA
expressions of both p53 and BTG2 were increased by up to 3–6
folds within 4 h of CRP treatment (Fig. 1A). We also conﬁrmed
CRP (25 lg/ml for 24 h) increased expressions of p53 and BTG2
proteins in THP-1 human monocytic cultured cell line, too
(Supplementary Fig. 1).
We harvested and cultured murine thioglycollate-elicited peri-
toneal monocytes/macrophages and conﬁrmed CRP-stimulated
expression of p53 and BTG2 proteins (25 lg/ml for up to 72 h) in
ex vivo conditions (Fig. 1B). Interestingly, parallel experiments
using p53/ littermates failed to show BTG2 upregulation by
CRP treatment whereas p53 upregulation was observed in
BTG2/ mice in 48 hours after CRP treatment, suggesting p53 is
required for the effect of CRP to complete BTG2 upregulation. Then
we localized BTG2, p53, and CRP proteins in atherosclerotic lesions
in LDLR//hCRPtg mice, whose serum CRP levels were maintained
over 10.0 mg/l. Immunohistochemistry analysis showed thatalization of CRP, p53 and BTG2 with monocytes/macrophages in the atherosclerotic
the changes of total and phosphorylated forms (‘p-p53’) of p53 and BTG2 proteins in
ted as a bar graph. Detection of p53 and BTG2 mRNA expressions by both semi-
raph. Data represent the mean ± S.D. of triplicates and were analyzed by unpaired t-
induced peritoneal macrophages derived from the 6-week-old C57/BL6 wild-type
were treated with CRP (25 lg/ml for up to 72 h), and the protein expressions of p53
mean ± S.D. of triplicates and were analyzed by unpaired t-test (⁄P < 0.05). (C) The
gainst CRP, p53, BTG2, and F4/80. Hematoxylin and eosin staining was applied as a
was stained with speciﬁc antibodies against BTG2 and CD68, a speciﬁc marker
Flour 488 (green color) or Rhodamine TRITC (red color). Nuclei were stained with
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monocytes/macrophages were positively stained with antibodies
speciﬁc for p53, BTG2, and CRP (Fig. 1C). We also performed the
immunoﬂuorescence staining in order to detect BTG2 expression
by human monocytes/macrophages resident in atherosclerotic
plaques. Human atherosclerotic coronary artery was stained with
speciﬁc antibodies recognizing either CD68(+) monocytes/macro-
phages or BTG2 protein and cell-bound antibodies were detected
by either Alexa Flour 488 (green color) or Rhodamine TRITC (red
color). The nucleus was stained by DAPI (blue color) as a back-
ground. The results clearly showed the co-localization of BTG2
with CD68(+) monocytes/macrophages. (Fig. 1D)
3.2. CRP-stimulated BTG2 expression facilitates apoptosis of
monocytes through the induction of G2/M cell cycle arrest
In order to quantify cells undergoing apoptotic changes, murine
thioglycollate-elicited peritoneal monocytes/macrophages were
prepared and treated with CRP (25 lg/ml/up to 48 h) and stained
with PI and annexin V, and ﬂowcytometry was performed. The pro-
portion of cells from wild type in sub-G0/G1 phase exceeded 60%
after 48 h of CRP treatment while the number of sub-G0/G1 cellsFig. 2. Regulation of CRP-induced apoptotic changes by BTG2. (A and B) Thioglycollate
(‘wild type’) male mice or BTG2/ (‘BTG2 KO’) littermates (n = 5 each) were cultured wit
the fraction of apoptotic cells in sub G0/G1 phase were assessed on the basis of DNA conte
annexin V-FITC, and the fraction of annexin-V-high early apoptotic cells were quantiﬁed
(25 lg/ml for up to 72 h), and then stained with 25 lg/ml PI. The fraction of apoptotic ce
experiments, human freshly-isolated monocytes were transfected with pCMV (‘moc
transfected with scrambled RNA or siRNA speciﬁc for BTG2 (‘BTG2 siRNA’), and were su
stained with PI and annexin V-FITC, and the fraction of annexin-V-high early apoptotic c
triplicates and were analyzed by unpaired t-test (⁄P < 0.05, ⁄⁄P < 0.01 vs. control). (E) H
25 lg/ml PI and labelled with 30 lM BrdU. The cell-associated BrdU was labeled with F
phase were analyzed by ﬂow cytometry. Prior to the treatment with CRP, monocyte
transfected with scrambled RNA or siRNA speciﬁc for BTG2(‘BTG2 siRNA’). Data represent
(p53DN or scrambled RNA)].from BTG2/ mice was signiﬁcantly lower than those from the
wild type (Fig. 2A). Moreover, the proportion of annexin V-high/
PI-high BTG2/ monocytes/macrophages were also signiﬁcantly
less than wild type cells (Fig. 2B), suggesting BTG2 may facilitate
the apoptotic change of CRP-treated monocytes. The effect of CRP
to induced apoptosis and the role of BTG2 were further conﬁrmed
using freshly-isolated human monocytes, in which CRP treatment
for 48 h or longer clearly increased numbers of cells in subG0/G1
phase (Fig. 2C). Same treatment also increased the number of
monocytes in annexin V-high/PI-high fraction and the transfection
with either p53DN or siRNA-BTG2 signiﬁcantly blocked the effect
of CRP to induce apoptotic cell death (Fig. 2D). In order to conﬁrm
the role of BTG2 on the development of apoptotic changes in
monocytes, BTG2 expression was induced by transfecting a
pcDNA3.1 vector encoding complete cDNA sequence of human
BTG2 to human monocytes, which enhanced the amount of BTG2
protein by more than 3 folds in 24 h (Supplementary Fig. 3A). Flow
cytometry clearly showed that the enhanced BTG2 expression sig-
niﬁcantly increased the number of monocytes in annexin V-high/
PI-high fraction (Supplementary Fig. 3B).
To investigate if CRP may affect cell cycle kinetics, the human
monocytes were synchronized at G1/S phase (G1 phase; 43%, S-induced peritoneal macrophages derived from the 6-week-old C57/BL6 wild-type
h CRP (25 lg/ml for 24 or 48 h) and stained with 25 lg/ml propidium iodide (PI) and
nt and quantiﬁed as% of the total cells (A). The cells were also co-stained with PI and
as% of the total cells, too (B). (C and D) Human monocytes were cultured with CRP
lls distributed in sub G0/G1 phase was obtained as described in A (C). In a subset of
k vector’) or pCMV-p53mt135 (‘p53DN’). Alternatively, human monocytes were
bsequently cultured for 48 hours with CRP (up to 25 lg/ml). The monocytes were
ells were quantiﬁed as% of the total cells (D). The data represent the mean ± S.D. of
uman monocytes were cultured with CRP (up to 25 lg/ml/48 h), and stained with
ITC-conjugated anti-BrdU antibody. The cell populations in G0/G1-, S-, and G2/M-
s were transfected with pCMV (‘mock vector’) or pCMV-p53mt135 (‘p53DN’), or
mean ± S.D. of triplicates and were analyzed by unpaired t-test [⁄P < 0.05 vs. control
Fig. 3. Regulations of CRP-induced p53 and BTG2 expression by the signals through CD32, Nox2, and DGKf. (A) Human monocytes were incubated with or without CRP
(25 lg/ml). In a subset of experiments, speciﬁc antibodies against CD64 or CD32 (10 lg/ml each), or NAC (an oxygen radical scavenger; 10 mM) were pre-treated 30 min prior
to CRP treatment, and then maintained for 24 h. Stimulation with lipopolysaccharide (100 ng/ml/24 h) was performed as a positive control. Protein levels of p53,
phosphorylated form of p53 (‘p-p53’) and BTG2 were quantiﬁed by immunoblot analysis (⁄P < 0.05 vs. untreated control). (B) Human monocytes were transfected with
scrambled RNA or siRNA speciﬁc for Nox2 (‘Nox2 siRNA’). Alternatively, human monocytes were transfected with pCMV (‘mock’) or pCMV-p53mt135 (‘p53DN’). After
incubation with CRP (25 lg/ml) for 24 h, p53 and BTG2 proteins in the cell lysates were measured by immunoblot analysis. (C) Human monocytes were transfected with
either scrambled RNA or siRNA speciﬁc for PKCd (‘PKCd siRNA’), treated with CRP (25 lg/ml/24 h) and BTG2 protein was detected in cell lysates was detected by
immunoblotting. (D and E) Human monocytes were transfected with either scrambled RNA or siRNA speciﬁc for DGKf (‘DGKzeta siRNA’). After incubation with CRP (25 lg/
ml/24 h), DGKf (D) and BTG2 proteins (E) in the cell lysates were measured by immunoblot analyses. Data represent the mean ± S.D. of triplicates and were analyzed by
unpaired t-test (⁄P < 0.05 vs. control; NS, not statistically signiﬁcant).
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up to 72 h and the amount of BrdU incorporation into the cells
was determined by ﬂowcytometry. Human monocytes was accu-
mulated at G2/M phase without further progression after the CRP
treatment and the transfection with either p53DN or siRNA-BTG2
prevented abolished CRP-induced cell cycle arrest (Fig. 2E).
3.3. CRP positively regulates BTG2 expression through a CD32/Nox2/
ROS/p53 pathway in monocytes
Our previous report described that CRP-bound CD32(FccRII)
generates ROS through activation of NADPH oxidase 4 (Nox4) [5].
Similarly, results of our immunoblot analysis also showed that
either treatment with anti-CD32 neutralizing antibody or NAC,
the scavenger of ROS, blocked the upregulatory effects of CRP on
p53 and BTG2 (Fig. 3A). Since our preliminary experiments con-
ﬁrmed the dominant Nox2 expression in human monocytes, we
therefore transfected siRNA-Nox2 to the freshly isolated human
monocytes, which suppressed Nox2 mRNA expression by more
than 55% (Supplementary Fig. 2). The transfection of siRNA-Nox2
signiﬁcantly inhibited CRP-stimulated expressions of both p53
and BTG2 (Fig. 3B). Moreover, the effect of CRP on BTG2 expression
was blocked by transfection with the dominant-negative form of
p53 (p53DN), suggesting the p53 is required for CRP-stimulated
BTG2 expression in human monocytes (Fig. 3B).Although our study results highly suggest that CRP-CD32-Nox2-
ROS-p53 pathway may exclusively upregulate BTG2 expression, a
previous report showed that BTG2 expression in monocyte-like
U937 cultured cells may be regulated through protein kinase C del-
ta (PKCd) without involvement of p53 [10]. Our immunoblotting
clearly proved that transfection of siRNA-PKCd, which knockdown
its expression by 75% (Supplementary Fig. 2), did not affect CRP-
stimulated BTG2 expression in human monocytes (Fig. 3C). Activa-
tion of CD32 can trigger the production of diacylglycerol (DAG), a
known negative regulator of BTG2 [11], whereas DAG is catabo-
lized to phosphatidic acid by diacylglycerol kinase-zeta (DGKf).
Interestingly, the treatment of human monocytes with CRP (up
to 10 lg/ml/24 h) enhanced expression of DGKf (Fig. 3D) and
CRP-induced BTG2 upregulation and p53 phosphorylation was dis-
appeared in human monocytes transfected with a speciﬁc siRNA
for DGKf (Fig. 3E), which suppressed mRNA expression of DGKf
over 60% (Supplementary Fig. 2).
4. Discussion
The present study provides a number of evidence that CRP may
affect cell cycle kinetics of monocytes via CD32(FccRII)/Nox2/ROS/
p53/BTG2 cascade, which induced G2/M phase arrest and eventu-
ally facilitated apoptotic death. CD32 had been described to trigger
apoptotic signals in granulocytes and eosinophils [12], and is
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polarize to M1 pro-inﬂammatory macrophages [13] Therefore,
our results suggest that one of the functional activities of CRP
may alleviate macrophage-driven pro-inﬂammatory responses.
Teupser et al. recently generated CRP-deﬁcient female mice with
LDLR/ C57BL/6 backgrounds, which had a relatively higher bur-
den of macrophages in the atherosclerotic lesion when compared
with control littermates [14]. However, the majority of other pre-
vious murine intervention studies did not show the compositional
change in the plaque including the number of apoptotic mono-
cytes/macrophages in the presence of CRP [15]. As a possible expla-
nation, CRP-bound apoptotic monocytes/macrophages may be
immediately removed via FccR-mediated phagocytosis [16]. In-
deed CRP can trigger a wide variety of cell signaling pathways
other than BTG2 upregulation, which may show complex contribu-
tions to the process of atherosclerosis and apoptotic changes may
not be an exclusive consequence of CRP stimulation in a subset
of monocytes/macrophages. As we described previously, mono-
cytes in the lesion might be replenished by CRP stimulation itself
through activating PLD/CCR2/MCP-1-dependent recruitment pro-
cess [9]. Moreover, other previous studies show that CRP also acti-
vates NFjB [17] and increases the production and secretion of GM-
CSF [18], which can trigger macrophages to undergo proliferation
and polarize to the M1 type.
The present study clearly identiﬁed BTG2 as a downstream
effector of CRP and BTG2 could be more speciﬁc target for the
retardation of inﬂammatory process mediated by monocytes. We
proved that the enhanced expression of BTG2 was potent enough
to orchestrate G2/M arrest and subsequently induce apoptotic
changes in CRP-treated monocytes. Our results show that p53 acti-
vation is required for the positive regulatory effect of CRP on BTG2
expression. The amount of total and phosphorylated form of p53
protein is increased in the advanced human plaques [19] and our
study showed that BTG2 protein is colocalized with p53 and CRP
in the early stage of atherosclerotic plaques enriched with mono-
cytes/macrophages. Therefore, BTG2 may conceivably contribute
to anti-atherosclerotic effects of p53 as described in earlier animal
intervention studies [20–22]. Our previous study [23] and others
[24] have examined in vivo tissue-speciﬁc expression of BTG2, in
which lymphoid organs (such as thymic cortex, spleen white pulp
and lymph node) lung and stomach express high levels of BTG2,
while myocardium showed little BTG2 expression. The functional
expression of BTG2 has been described as negatively correlated
with the severity of various cancers and the inﬂammatory condi-
tions in pancreas [25]. Taken together, our results raise the possi-
bility that targeting the BTG2-speciﬁc pathway rather than CRP
itself can be more selective and effective strategy for the suppres-
sion of various inﬂammatory and cancerous conditions including
the growth of atherosclerotic lesions.
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